GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codon AG (CHIX:CNWKd) » Definitions » LT-Debt-to-Total-Asset

Codon AG (CHIX:CNWKD) LT-Debt-to-Total-Asset : 0.38 (As of Jun. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Codon AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Codon AG's long-term debt to total assests ratio for the quarter that ended in Jun. 2022 was 0.38.

Codon AG's long-term debt to total assets ratio increased from Jun. 2021 (0.25) to Jun. 2022 (0.38). It may suggest that Codon AG is progressively becoming more dependent on debt to grow their business.


Codon AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for Codon AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codon AG LT-Debt-to-Total-Asset Chart

Codon AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.32 0.36 0.19 0.22

Codon AG Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.19 0.25 0.22 0.38

Codon AG LT-Debt-to-Total-Asset Calculation

Codon AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )/Total Assets (A: Dec. 2021 )
=5.771/26.316
=0.22

Codon AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

LT Debt to Total Assets (Q: Jun. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2022 )/Total Assets (Q: Jun. 2022 )
=5.845/15.563
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codon AG  (CHIX:CNWKd) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Codon AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Codon AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Codon AG (CHIX:CNWKD) Business Description

Traded in Other Exchanges
N/A
Address
Warthestrasse 21, Teltow, DEU, 14513
Codon AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells (autologous chondrocytes). CODON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated.

Codon AG (CHIX:CNWKD) Headlines

No Headlines